Regulators Seek Contempt Charges Against Martin Shkreli for Industry Ban Violations

The Federal Trade Commission and seven state attorneys general have filed a motion to hold Martin Shkreli in contempt for allegedly violating a 2022 lifetime ban from the pharmaceutical industry. The injunction prohibits Shkreli from owning pharmaceutical stocks and making public statements intended to influence the sector.

Regulators allege that Shkreli repeatedly traded pharmaceutical equities and utilized social media livestreams to discuss and influence the management of multiple drug companies. The filing cites specific instances of trading activity and public commentary occurring between 2022 and 2026.

Authorities are requesting that the court mandate the Authorities are requesting that the court mandate the divestment of all pharmaceutical holdings and the disgorgement of profits derived from prohibited trading. The motion also seeks the establishment of escalating penalties, including potential incarceration, to ensure future compliance with the industry ban.

The legal action underscores the challenges of enforcing permanent industry exclusions against individuals with high-profile digital platforms. Regulators contend that the current conduct demonstrates a deliberate disregard for federal judicial orders.